|
業務類別
|
Biotechnology |
|
業務概覽
|
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx)to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions. |
| 公司地址
| 10955 Alexandria Way, Suite 100, San Diego, CA, USA, 92121 |
| 電話號碼
| +1 858 766-9912 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.boundlessbio.com |
| 員工數量
| 28 |
| Ms. Jessica Oien, J.D. |
Chief Legal Officer and Corporate Secretary |
-- |
28/04/2026 |
| Dr. Robert Doebele, M.D.,PhD |
Chief Medical Officer |
美元 458.51K |
28/04/2026 |
| Mr. David A. Hinkle |
Senior Vice President, Finance, Controller, and Corporate Treasurer |
-- |
28/04/2026 |
| Mr. Christian Hassig, PhD |
Chief Scientific Officer |
美元 478.30K |
28/04/2026 |
| Mr. Zachary D. Hornby |
President, Chief Executive Officer and Director |
美元 638.00K |
28/04/2026 |
|
|
| Dr. Nancy C. Whiting, Pharm.D. |
Independent Director |
28/04/2026 |
| Dr. Jonathan E. Lim,M.D. |
Chairman of the Board |
28/04/2026 |
| Ms. Jennifer Lew |
Independent Director |
28/04/2026 |
| Ms. Kristina M. Burow |
Independent Director |
28/04/2026 |
| Dr. James Christensen, PhD |
Independent Director |
28/04/2026 |
| Mr. Zachary D. Hornby |
President, Chief Executive Officer and Director |
28/04/2026 |
|
|
|
|
